Amylyx Pharmaceuticals, Inc. (AMLX) - What Are Researchers Thinking About This Stock?

Amylyx Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is broadly positive: Nine analysts give Amylyx a “Moderate Buy” consensus rating, with an average 12-month price target of $43.71. Recent target prices include $55 from HC Wainwright and $57 from Guggenheim.
  • Shares opened at $26, compared with a 52-week range of $10.83 to $41.14. The company reported a quarterly loss of $0.38 per share, in line with expectations.
  • Insiders sold 60,374 shares worth about $1.82 million over the past three months; institutional investors own 95.84% of the stock.
  • Five stocks to consider instead of Amylyx Pharmaceuticals.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $43.71.

AMLX has been the subject of a number of recent research reports. Wolfe Research raised shares of Amylyx Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 17th. Robert W. Baird increased their target price on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an "outperform" rating in a research report on Wednesday, August 19th. Mizuho increased their target price on Amylyx Pharmaceuticals from $38.00 to $39.00 and gave the company an "outperform" rating in a research report on Tuesday, November 10th. HC Wainwright reiterated a "buy" rating and issued a $55.00 price target on shares of Amylyx Pharmaceuticals in a report on Thursday. Finally, Guggenheim boosted their price target on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a "buy" rating in a research report on Thursday, August 27th.

View Our Latest Stock Analysis on AMLX

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, Director M Jr sold 30,000 shares of Amylyx Pharmaceuticals stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $27.70, for a total value of $831,000.00. Following the transaction, the director owned 782,881 shares in the company, valued at $21,685,803.70. The trade was a 3.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Frates sold 10,810 shares of the business's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $32.36, for a total transaction of $349,811.60. Following the completion of the transaction, the chief financial officer owned 233,625 shares of the company's stock, valued at $7,560,105. This represents a 4.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 60,374 shares of company stock worth $1,815,257 in the last three months. 10.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AMLX. BlackRock Inc. acquired a new position in Amylyx Pharmaceuticals during the 2nd quarter valued at about $158,534,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Amylyx Pharmaceuticals by 10.4% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 173,407 shares of the company's stock worth $3,114,000 after acquiring an additional 16,318 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Amylyx Pharmaceuticals in the second quarter worth about $705,000. Elmind Capital LP purchased a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth about $2,011,520. Finally, Nantahala Capital Management LLC purchased a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth about $8,740,845. Hedge funds and other institutional investors own 95.84% of the company's stock.

Amylyx Pharmaceuticals Stock Performance

NASDAQ AMLX opened at $26.00 on Friday. Amylyx Pharmaceuticals has a one year low of $10.83 and a one year high of $41.14. The company has a market capitalization of $3.34 billion, a price-to-earnings ratio of -18.05 and a beta of -0.09. The company's 50-day simple moving average is $29.05 and its two-hundred day simple moving average is $21.09.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share for the quarter, hitting the consensus estimate of ($0.38). Equities analysts expect that Amylyx Pharmaceuticals will post -1.50 earnings per share for the current fiscal year.

Amylyx Pharmaceuticals Company Profile

(Get Free Report)

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Recommended Stories

Analyst Recommendations for Amylyx Pharmaceuticals (NASDAQ:AMLX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Amylyx Pharmaceuticals Right Now?

Before you consider Amylyx Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.

While Amylyx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines